These findings may help explain the post-treatment reduction in galectin-3 levels observed in CD patients in our study and suggest a potential role for galectin-3 as a biomarker for monitoring the efficacy of corticosteroid treatment in IBD. The gene discussed is LGALS3; the disease is inflammatory bowel disease.